Drugs / Clobetasol
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04685031 | Feb → Apr 2021 | phlebitis | Komar University of Science and Technology | Unknown | No outcome recorded |
| Phase 1/2 | NCT02319616 | Nov 2016 → Feb 2019 | toxic epidermal necrolysis | University of California, Davis | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 2 | NCT01557517 | Mar 2012 → Jun 2017 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01407471 | Sep 2011 → May 2012 | skin atrophy | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00297011 | Sep 2004 → Mar 2007 | herpes labialis | University of Utah | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00715975 | Jul 2008 → May 2010 | psoriasis | Azidus Brasil | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | Missed primary |
| Phase 3 | NCT01699412 | Aug 2008 → Jul 2012 | graft versus host disease, mouth disorder | Grupo de Estudos Multicentricos em Onco-Hematologia | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07276802 | Apr → Dec 2026 expected | cataract | Research Insight LLC | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03453190 | Feb 2018 → Mar 2020 | psoriasis | Washington Dermatology Center | Unknown | No outcome recorded |
| Phase 4 | NCT00779792 | Sep → Nov 2008 | occupational dermatitis | Odense University Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01987076 | Oct 2013 → Oct 2015 | drug rash with eosinophilia and systemic symptoms | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT00470392 | May 2007 → Jul 2010 | psoriasis | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy14 trials | ||||||
| Phase 1 | NCT06504160 Background | May 2025 → Dec 2026 expected | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT02680717 Comparator | Mar 2016 → May 2017 | scleroderma | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT03399526 Comparator | Feb → May 2013 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT06742333 Comparator | Jul 2025 → Jul 2028 expected | psoriasis | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 2 | NCT06752343 Comparator | Jun 2023 → Oct 2024 | lichen planus, oral | Wroclaw Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03961126 Comparator | Sep 2017 → Dec 2019 | vulvar lichen sclerosus | La Fe Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03286582 Comparator | Sep 2017 → Dec 2018 | bullous pemphigoid | TWi Biotechnology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02744378 Comparator | Jun 2014 → Jul 2015 | lichen planus, oral | University of Peradeniya | Completed | No outcome recorded |
| Phase 2 | NCT00393263 Comparator | Oct 2006 → Oct 2009 | vulvar lichen sclerosus | Center for Vulvovaginal Disorders | Completed | No outcome recorded |
| Phase 3 | NCT05010421 Comparator | Nov 2021 → Jul 2025 | lichen sclerosus et atrophicus | Ruhr University of Bochum | Completed | No outcome recorded |
| Phase 4 | NCT04207931 Comparator | Apr 2018 → Nov 2026 expected | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT01205880 Comparator | Dec 2009 → Jan 2010 | psoriasis | Emer, Jason, M.D. | Completed | No outcome recorded |
| — | NCT06135402 Comparator | Nov 2023 → Nov 2027 expected | lichen sclerosus et atrophicus | Kantonsspital Winterthur KSW | Recruiting | No outcome recorded |
| — | NCT00769184 Background | Oct 2008 → Apr 2009 | psoriasis | NeoStrata Company, Inc. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-09 | Harrow Inc | Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals harrow.com ↗ |
| 2025-06-09 | Formosa Pharmaceuticals, Inc. | Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals formosapharma.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clobetasol | “postoperative administration of topical clobetasol 0.05% (Byqlovi) BID for 14 days to deliver corticosteroid” NCT07276802 ↗27“clobetasol: 2 applications / day along with LCD application 2 applications/day” NCT00769184 ↗ “Clobetasol, Betamethasone Dipropionate, or Fluocinonide” NCT04207931 ↗ “* clobetasol 0.05%” NCT01313221 ↗ |
| Known as | Byqlovi | “postoperative administration of topical clobetasol 0.05% (Byqlovi) BID for 14 days to deliver corticosteroid” NCT07276802 ↗ |
| Known as | clobetasol propionate | “The objective of this study is evaluating the efficacy and tolerability of the drug Halobetasol propionate cream formulation as a treatment in patients with plaque psoriasis...” NCT00715975 ↗3“Superpotent topical corticosteroids such as clobetasol propionate are highly effective in treating plaque psoriasis but are not indicated for long term use due to their side effects.” NCT00769184 ↗ “Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days.” NCT00470392 ↗ “Clobex® Spray (clobetasol propionate)” NCT01205880 ↗ |
| Known as | Psorex | “The objective of this study is evaluating the efficacy and tolerability of the drug Halobetasol propionate cream formulation as a treatment in patients with plaque psoriasis...” NCT00715975 ↗ |
| Action | Inhibit | “suppression of TNF signaling” NCT02319616 ↗ |
| Modality | Small molecule | “topical ultrapotent corticosteroids such as clobetasol” PMID 21353334 ↗ Feb 2011 |
| Route | Topical | “Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial.” PMID 19143902 ↗ Jan 2009 |
| Target | TNF | “suppression of TNF signaling” NCT02319616 ↗ |